Ranitidine recall – Golden State Medical Supply

Tue, 11/19/2019 - 13:52

On November 18, 2019, Golden State Medical Supply (GSM) issued a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will send a letter to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Product Description

GSMS NDC

GSMS Lot #

Expiration Date

RANITIDINE HCl 150MG CAPSULES

51407-097-05

GS023970

10/31/2020

GS026108

10/31/2020

GS026099

10/31/2020

GS026838

10/31/2020

GS025702

10/31/2020

GS027272

10/31/2020

GS027273

05/31/2021

RANITIDINE HCl 300MG CAPSULES

51407-098-01

GS023971

10/31/2020

GS025527

10/31/2020

GS025526

10/31/2020

GS026114

10/31/2020

GS025813

10/31/2020

GS026189

10/31/2020

GS027555

07/31/2021

GS026190

05/31/2021

GS026220

05/31/2021

GS026584

05/31/2021

GS027139

05/31/2021

GS027554

05/31/2021

Additional information is available on the FDA’s website:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/golden-state-medical-supply-inc-issues-voluntary-nationwide-recall-ranitidine-hydrochloride-150mg

Last updated: Tue, 11/19/2019 - 14:13

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.